title: Epidemiology of Candida Infections in HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University.
abstract: OBJECTIVE
  To identify the epidemiology of candida isolations in HRH Princess Maha Chakri Sirindhorn Medical Center and the sensitivity of all candida species to fluconazole.
  
  
  METHODS
  Two hundred of Candida albicans and other Candida species from clinical specimens were collected from microbiological department between January 2010 and April 2012. All Candida were identified by standard methods and the sensitivity of fluconazole was tested by using fluconazole E test test.
  
  
  RESULTS
  There were 8 species of Candida in this study including: C. albicans (n = 94), C. tropicalis (n = 66), C. glabrata (n = 11), C. guilliermondii (n = 10), C. parapsilosis (n = 9), C. zeylanoides (n = 4), C. keyfr (C. pseudotropicalis) (n = 2), C. lusitaniae (n = 1), Candida species (n = 3). The percentage of non-albicans Candida spp. was slightly higher than C. albicans (53% vs. 47%). C. tropicalis was identified as the highest percentage of all non-albicans Candida spp. Fluconazole resistant strains were detected among C. albicans (35.71%), C. tropicalis (13.85%), C. guilliermondii (20.0%), and C. zeylanoides (50.0%). The common spp. with highest percentage of resistant strain was C. albicans.
  
  
  CONCLUSIONS
  Fluconazole could be used as thefirst-line antifungal for candidiasis at HRH Princess Maha Chakri Sirindhorn Medical Center. Empirical treatment with amphotericin B and steppingdown tofluconazole when sensitivity suggested might be the recommendation for severe cases in our setting.
authors.forename: Woraphot
authors.initials: W
authors.lastname: Tantisiriwat
authors.forename: Somchai
authors.initials: S
authors.lastname: Santiwattanakul
mesh_terms: D000046:Academic Medical Centers; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000302:isolation & purification*; D002176:Candida albicans / Q000302:isolation & purification; D002177:Candidiasis / Q000453:epidemiology*; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D011446:Prospective Studies; D014481:United States
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole